Description
Trimovis is a corticosteroid injectable suspension containing Triamcinolone Acetonide USP 40 mg per 1 ml, intended for intramuscular (I.M.) administration only. This formulation is designed to provide potent anti-inflammatory and immunosuppressive effects in patients suffering from a wide range of conditions including allergic disorders, rheumatoid arthritis, dermatologic conditions, and other systemic inflammatory diseases.
Triamcinolone Acetonide works by inhibiting the release of inflammatory mediators and suppressing immune system overactivity, offering relief from pain, swelling, and tissue damage. Its prolonged duration of action allows for reduced dosing frequency, improving patient adherence in chronic conditions.
Trimovis is manufactured by ANVIS and packaged in a 1 ml sterile vial, enclosed within a branded carton marked with a distinctive colorful tree icon. The labeling supports clear identification and ensures pharmaceutical integrity and safe handling. Recommended for use under medical supervision, Trimovis is commonly administered in hospital, clinical, and outpatient settings for both acute and maintenance therapy.
